Pulse Biosciences Announces Preliminary Fourth Quarter and Full Year 2021 Financial and Operational Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced preliminary unaudited fourth quarter 2021 financial and operational results. Recent Highlights: Preliminary unaudited full year 2021 revenue is expected to be in the range of $1.3...

Click to view original post